CRO’s grant year (2012-2013) ended on May 31st. During May, we earned 5 treatment credits and 8.1 control credits. This grant year we have earned 93.9 treatment credits and 109.5 cancer control credits. Good news is we have exceeded our NCI target for control credit of 80 for this grant year by 29.1. YEA! We fell short of meeting our NCI target credits of 110 by 16.1. Combined we have exceeded our NCI target of 190 credits this year by 9.4 earning 203.4 total credits. We did very well! Thanks to all of you for enrolling your patients on clinical trials. Exceeding our NCI target the past two years will be looked upon favorably as we prepare our NCORP (NCI Community Oncology Research Program) grant over the next months.

Farwell for Dr. Carolla
A retirement party for Dr. Carolla was held on Thursday, May 30th from 5p - 6:30p at Touch Restaurant. Dr. Jay Carlson, CRO’s new Principal Investigator, thanked Dr. Carolla for his 5 years of service at CRO and recognized his many accomplishments. Dr. Carolla’s family, friends, CRO investigators and local CRO staff joined in the celebration. Dr. Robert Carolla, CRO PI from 2008 – 2013, Dr. Wendall Goodwin, CRO PI from 1987 – 2008 and the new CRO PI as of June 1, 2013 Dr. Jay Carlson posed for a photo at the party.

New CRO Affiliations
It is official, June 1, 2013 Mercy Hospital St. Louis, St. Louis Cancer and Breast Institute and Good Samaritan Regional Health Center, in Mt. Vernon, Illinois are CRO affiliates. Ozark Medical Center in West Plains re-contacted CRO regarding an affiliation. This possibility is being explored.

Study Profile
SWOG S1216 “A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer.” The primary objective of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide. Patients may have had prior surgery, palliative radiotherapy and neoadjuvant and/or adjuvant hormonal therapy, within the past 36 months. They must have sufficient cardiac, hematologic and renal function. Those with brain metastasis are not eligible.
**New Studies Approved in May, 2013**

**Opened at Cox and Mercy Springfield**

**SWOG S1216** A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

**New Protocols Opened at Mercy for St. Louis in May 2013:**
These studies were previously opened with the St. Louis CCOP through the Mercy St. Louis IRB. The IRB in St. Louis has requested that the Springfield IRB activate this study to continue access.

**SWOG S0702** A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment

**SWOG S0819** A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel/Bevacizumab or Carboplatin/Paclitaxel or with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

**RTOG R0622** A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-DRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy

**Studies Permanently Closed to Enrollment at Cox & Mercy in May 2013**

**GOG-01 86J** A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma